{"id":"NCT00702715","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)","officialTitle":"A Multi-center, Parallel-group, Comparative Trial Evaluating the Efficacy, Pharmacokinetics and Safety of 4.0 mg/kg Sugammadex Administered at 1-2 PTC in Subjects With Normal or Severely Impaired Renal Function","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09-24","primaryCompletion":"2010-03-15","completion":"2010-03-15","firstPosted":"2008-06-20","resultsPosted":"2011-04-11","lastUpdate":"2017-05-16"},"enrollment":69,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anesthesia"],"interventions":[{"type":"DRUG","name":"sugammadex","otherNames":["Org 25959"]}],"arms":[{"label":"Participants with severe renal impairment","type":"EXPERIMENTAL"},{"label":"Participants with normal renal function","type":"ACTIVE_COMPARATOR"}],"summary":"The current trial was designed to investigate the effects of 4.0 mg.kg-1 of sugammadex on efficacy, safety and pharmacokinetics in subjects with severe renal impairment in comparison to subjects with normal renal function.","primaryOutcome":{"measure":"Time to Recovery of the T4/T1 Ratio to 0.9.","timeFrame":"start of administration of sugammadex to recovery from neuromuscular blockade","effectByArm":[{"arm":"Participants With Severe Renal Impairment","deltaMin":205,"sd":null},{"arm":"Participants With Normal Renal Function","deltaMin":112,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25829395"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":35},"commonTop":["Procedural pain","Procedural hypotension","Procedural nausea","Anaemia","Nausea"]}}